nivolumab,ipilimumab
bms
['niche-2']
now at esmo 2022: the niche-2 study being presented by at the presidential symposium #2 #esmo22 #research #cancerresearch 
The Netherlands Cancer Institute (NKI): at the international forefront of cancer research and treatment for over 100 years. Our Dutch account is @hetAVL.